-
2024-518139-12-00
4
locally advanced or metastatic Pancreatic ductal adenocarcinoma
-
2025-521331-36-00
10
Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
-
2025-522790-10-00
4
Non Small Cell Lung Cancer
-
2025-523683-20-00
4
Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
-
2025-522892-27-00
4
2026-03-21
Bronchiectasis
-
2023-505172-29-00
4
2025-04-24
Resectable Non-small Cell Lung Cancer
-
2023-505046-26-00
5
2026-05-07
Colon carcinoma
-
2022-501557-36-00
4
2025-12-19
PR3-ANCA granulomatosis with polyangiitis (Wegener’s)
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2024-519052-82-00
4
2025-06-30
pleural mesothelioma
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2024-514304-14-00
1
2024-10-08
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
-
2023-508429-29-00
4
2024-09-26
Progressive Pulmonary Fibrosis
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2024-515297-27-00
5
2024-08-14
colon carcinoma
-
2023-509761-21-00
5
2024-07-08
Metastatic colorectal cancer
-
2023-503412-33-00
5
2024-03-29
Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
-
2023-504323-25-01
5
2024-03-19
breast cancer
-
2022-501057-36-00
5
2023-10-24
ANCA-associated vasculitis
-
2022-501335-16-00
10
2023-01-16
Interstitial lung disease
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-515945-40-00
10
2022-05-02
Non small cell lung cancer
-
2024-513427-17-00
6
2021-05-20
Well controlled severe allergic asthma
-
2024-515019-22-00
5
2021-02-26
Septic shock